Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S Schaefer
{"title":"更正:斯帕妥珠单抗联合铂双化疗与或不联合卡那珠单抗治疗未选择 PD-L1 的转移性 NSCLC 患者。","authors":"Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S Schaefer","doi":"10.1186/s12885-024-13210-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"24 1","pages":"1436"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580551/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.\",\"authors\":\"Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S Schaefer\",\"doi\":\"10.1186/s12885-024-13210-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9131,\"journal\":{\"name\":\"BMC Cancer\",\"volume\":\"24 1\",\"pages\":\"1436\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580551/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12885-024-13210-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-024-13210-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
期刊介绍:
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.